AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01964534
Drug: simplified LV5FU2
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
Trial: NCT01057433
Drug: Pitavastatin (NK-104)
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pitavastatin (NK-104) 4 mg once daily (QD)
Trial: NCT01057433
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lopinavir/ritonavir 800 mg/200 mg
Trial: NCT00134199
Drug: sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00210067
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection
DrugBank: Denufosol (DB04983)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00426829
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
Trial: NCT03283371
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As specified in the treatment arm.
Trial: NCT04945499
Drug: d-glucose
RxNorm normalized name: D-glucose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using d-glucose as an contrast agent on CEST MR Imaging
Trial: NCT01747707
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01747707
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01747707
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT03272009
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT03272009
Drug: peg-interferon alfa-2a
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ready-to-Use pre-filled syringes for subcutaneous injection
Trial: NCT03785405
Drug: sacubitril/valsartan
RxNorm normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)
Trial: NCT04110054
Drug: S-600918
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT04363866
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
Trial: NCT02198313
Drug: BIIX 1 XX - D2
RxNorm normalized name: 1α-hydroxyvitamin D2
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02198313
Drug: BIIX 1 XX - D3
RxNorm normalized name: 1α-hydroxyvitamin D3
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01216644
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600 mg/m²d1 i.v. every 2 weeks
Trial: NCT01216644
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m², d1, i.v., every 2 weeks
Trial: NCT01216644
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m2, d1, i.v., every 2 weeks
Trial: NCT01216644
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, d1, i.v., every 3 weeks
Trial: NCT01216644
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m², d1, i.v., every 3 weeks
Trial: NCT01216644
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², d1-d21, i.v., every 3 weeks
Trial: NCT00963469
Drug: montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg tablet orally once daily in the morning for 4 weeks
Trial: NCT00963469
Drug: Comparator: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loratadine 10 mg tablet orally once daily in the morning for 4 weeks
Trial: NCT01920516
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
Trial: NCT03196206
Drug: BMS-986177
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Suspension
Trial: NCT00651911
Drug: urate oxidase
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
Trial: NCT00004840
Drug: thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01924260
Drug: alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01924260
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01719627
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unique dose of Maraviroc 300mg
Trial: NCT01719627
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unique dose of Maraviroc 600mg
Trial: NCT00570700
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150mg (3 pills) orally daily for as long as the drug benefits
Trial: NCT00094016
Drug: beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002755
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002755
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00448669
Drug: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
RxNorm normalized name: emtricitabine / tenofovir disoproxil fumarate Pill
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00039234
Drug: histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04287985
Drug: Low Dose-VIS649
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose Level = Low
Trial: NCT04287985
Drug: Medium Dose-VIS649
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level = Medium
Trial: NCT04287985
Drug: High Dose-VIS649
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level = High
Trial: NCT01571804
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
Trial: NCT01571804
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: two capsules of pregabalin 150 mg 1 hr before surgery
Trial: NCT02638337
Drug: Ospemifene
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 mg tablet
Trial: NCT02988089
Drug: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all patients need these two drugs.
Trial: NCT02988089
Drug: amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salvage therapy for failed eradication if failed with AST guided eradication therapy
Trial: NCT02008981
Drug: Curcuma longa
RxNorm normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Trial: NCT02008981
Drug: Angelica sinensis
RxNorm normalized name: ANGELICA SINENSIS ROOT
DrugBank: Angelica sinensis root (DB14336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Trial: NCT02008981
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Trial: NCT02350517
Drug: Paclitaxel+Nedaplatin+Endostar
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
Trial: NCT00188552
Drug: pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00188552
Drug: α-Tocopherol
RxNorm normalized name: d-α-tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02357472
Drug: dehydroepiandrosterone
RxNorm normalized name: Dehydroepiandrosterone
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
Trial: NCT03951805
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously SC once weekly. Starting dose will be 70U.
Trial: NCT03951805
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously SC once daily.The starting dose will be 10U.
Trial: NCT01154387
Drug: Anti-Thymocyte Globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
Trial: NCT01154387
Drug: TOL101
RxNorm normalized name: TOL101
DrugBank: TOL-101 (DB16980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
Trial: NCT01154387
Drug: TOL101
RxNorm normalized name: TOL101
DrugBank: TOL-101 (DB16980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
Trial: NCT01154387
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration started by 6 days post-transplantation and continued for 6 months
Trial: NCT01154387
Drug: Mycophenolate mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration started by Day 1 post-transplantation and continued for 6 months
Trial: NCT00141297
Drug: PD-0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
Trial: NCT01695954
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
Trial: NCT01695954
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir 400 mg tablets x 2 taken daily in Arm B
Trial: NCT01695954
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 100 mg tablets taken daily in Arm B
Trial: NCT01695954
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg tablets taken at bedtime in Arm A
Trial: NCT03921866
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib
Trial: NCT04187898
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.
Trial: NCT04481412
Drug: Topical cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
Trial: NCT04481412
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Minoxidil 5% that will be applied once daily.
Trial: NCT04477265
Drug: Solifenacin Succinate 5mg/tab daily
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will be taking oral medication for 3 months
Trial: NCT00686777
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 400 mg/day orally
Trial: NCT02969798
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/day
Trial: NCT02969798
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/day
Trial: NCT02969798
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the dose will increase from 15 mg/day to 30 mg/day at month two
Trial: NCT02969798
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: starting at 1000 mg/day and increased to 2000 mg/day at month 2.
Trial: NCT01622439
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
Trial: NCT01622439
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Trial: NCT01622439
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
Trial: NCT01622439
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
Trial: NCT03284463
Drug: Glibenclamide
RxNorm normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
Trial: NCT02160080
Drug: Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
Trial: NCT04701008
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
Trial: NCT03863184
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acalabrutinib, oral, 100 mg BID, continuous
Trial: NCT03863184
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
Trial: NCT03863184
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
Trial: NCT04038359
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phosphoinositide 3-kinase (PI3K) inhibitor
Trial: NCT01691079
Drug: ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium bromide administered before exercise.
Trial: NCT00274469
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscular injection
Trial: NCT00274469
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg oral tablet
Trial: NCT00445315
Drug: PF-00868554
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg BID
Trial: NCT00445315
Drug: PF-00868554
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg BID
Trial: NCT00445315
Drug: PF-00868554
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID
Trial: NCT00445315
Drug: PF-00868554
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg TID
Trial: NCT03908060
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One intravenous administration of methadone (0.2 mg/kg ideal body weight)
Trial: NCT03908060
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One intravenous administration of morphine (0.2 mg/kg ideal body weight)
Trial: NCT04139434
Drug: LP-108 and azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
Trial: NCT02669771
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral